title: Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
authors.forename: Mary G
authors.initials: MG
authors.lastname: Boy
authors.forename: Cunshan
authors.initials: C
authors.lastname: Wang
authors.forename: Bethanie E
authors.initials: BE
authors.lastname: Wilkinson
authors.forename: Vincent Fung-Sing
authors.initials: VF
authors.lastname: Chow
authors.forename: Alan T
authors.initials: AT
authors.lastname: Clucas
authors.forename: James G
authors.initials: JG
authors.lastname: Krueger
authors.forename: Anderson S
authors.initials: AS
authors.lastname: Gaweco
authors.forename: Samuel H
authors.initials: SH
authors.lastname: Zwillich
authors.forename: Paul S
authors.initials: PS
authors.lastname: Changelian
authors.forename: Gary
authors.initials: G
authors.lastname: Chan
mesh_terms: D000328:Adult; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D010880:Piperidines; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib